M0250 Adm tocilizu covid-19 second
M-Codes
Also known as: COVID tocilizumab second, toci COVID second dose
Administration of tocilizumab for coronavirus disease 2019 (COVID-19), second dose. Continuation of immune modulation therapy for severe COVID-19.
Clinical Context
Administered as subsequent dose in hospitalized COVID-19 patients requiring continued immune suppression to prevent acute respiratory distress syndrome.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.